The9 Ltd
NCTY
IREN Ltd
IREN
Bitdeer Technologies
BTDR
Canaan
CAN
CleanSpark
CLSK
US Stock MarketDetailed Quotes
CVKD Cadrenal Therapeutics
- 19.491
- +0.161+0.83%
Trading Mar 19 09:35 ET
36.64MMarket Cap-2.23P/E (TTM)
19.580High19.491Low2.10KVolume19.580Open19.330Pre Close41.02KTurnover0.16%Turnover RatioLossP/E (Static)1.88MShares22.90152wk High4.92P/B25.39MFloat Cap5.40052wk Low--Dividend TTM1.30MShs Float101.250Historical High--Div YieldTTM0.46%Amplitude5.400Historical Low19.535Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Cadrenal Therapeutics Stock Forum
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Tuesday, 4th March at 8:00 am
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a late-stage biopharmaceutical company focused on the development of spec...
4 mins ago
Cadrenal Therapeutics Announces Collaboration Agreement With Abbott in Support of Pivotal Study of Tecarfarin in Patients With Heartmate 3™ Lvad
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted a recently published manuscript in the Journal of Cardiac Failure, evaluating the relationship between time in therapeutic range (TTR) management quality and clinical outcomes for left ventricular assist device (LVAD) patients. The findings emphasize the need for improved anticoagulation th...
Larger Image: tradingview.com...
$Cadrenal Therapeutics (CVKD.US)$
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) has presented new data from the ARIES-HM3 trial at the ISHLT conference, showing the significant impact of anticoagulation quality in LVAD patients. The trial highlighted the deficiencies of warfarin and introduced tecarfarin, a novel VKA, as a potential replacement. T...
No comment yet